Algernon Pharmaceuticals Inc (QB) (AGNPF) Quote

Outstanding: 27,301,179 for November 6, 2024

Monthly 5th Report

https://webfiles.thecse.com/10._Algernon_-_CSE_Form_7_-_October_2024.pdf?dcBppEBh75EfB.9rOF7uL_qdPPt86f8S

400 Warrants issued in October @ $0.52 $AGN or $0.374 $AGNPF price (Market never went over $0.0688 $AGNPF the whole month of October and Buying Open Market would have been like 2,000 shares vs the same cost of 400 Warrants)

NOTICE OF AMENDMENT OF WARRANT TERMS

They expire November 5th and change the date to expire May 5th 2025

But look how they left the price unchanged from to still $0.52 $AGN or $0.374 $AGNPF

Looks Bullish but I DON’T FEEL IT

https://webfiles.thecse.com/Final_Algernon_CSE-Form_13-Amendment-of_Warrant_Terms_-_Nov._2024.pdf?QLyYlN5KeNvboxvVrkU5kuy7e1jImpz4

I have completely lost track of what might be next here with AGN. What are we waiting for? Is there anything going on at all? There is never any news, no video interviews, nothing to follow...what is potentially next???

I still like management AND this stock..
I know.. oh well..
buy low!

I am the worst stock picker ever..
Haha

Outstanding: 27,300,779 for September 10, 2024

Monthly 5th Report

https://webfiles.thecse.com/8._Algernon_-_CSE_Form_7_-_August_2024.pdf?T0RnoT2MZl1XzWpHbNPjzdACkTKflj8P

Actually one of few stocks I would own at this point… God help us all if the Marxists win .. they usually kill people before they take power..

By all rights
The previous shareholders lost everything with failures..
You are buying a different proposition and insiders are invested..
It’s a better shot with DMT ..

I like it

Needed cash but if able will buy back in

Offering is $0.0892 $AGNPF or $0.12 $AGN

Someone and Insiders Buying the Offering

But Insiders except Kinley has also sold most those others held on the last real run which does look bad and would expect them to also sell these bought when price is up - JMO

https://ceo.ca/agn

My thinking is
Don’t sell

CRY or LAUGH My Ass Off

To me it’s sad but someone is collecting shares for some reason - Volume just not there for selling for the same @ the Market Price

Algernon Pharmaceuticals Announces Increase to Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE)

https://webfiles.thecse.com/2024-08-13_Algernon_Pharmaceuticals_Announces_Increase_to_209.pdf?80FkHRyx35jcD3V97cSqfn8Fr.W2Qq5G

Outstanding: 25,340,779 for August 7, 2024

Monthly 5th Report

https://webfiles.thecse.com/7._Algernon_-_CSE_Form_7_-_July_2024.pdf?xHwunyx5dN5BN0JDisNSwQ2.pH76QXG0

Closing of Private Placement

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Closing-of-Private-Placement?id=448835
The Company paid cash finder’s fees totaling $5,376 and issued 44,800 finders warrants to eligible finders for investors introduced to the Company by the eligible finder.

Who Bought Shares ••• (Units)

https://webfiles.thecse.com/Algernon_CSE_Form_9_-_August_2024_Final.pdf?MfzQpVMdcPsP0LHNMqkugZLHRQ9oMPG.

Issued and outstanding securities following issuance:

25,340,779 Shares Outstanding

25.5M Outstanding if closing tomorrow doesn’t change


25,340,779 Outstanding if closing the same that was released today and it Close 08/01/2024

Add the Broker pay which probably some in Cash and again paid the same in shares

In the past it was 8% cash and 8% shares and should read the 1st notice of this Offering

https://webfiles.thecse.com/Algernon_CSE_Form_9_-_Juy_2024.pdf?xwI_B_aF3yzpRKAETnDXGgVEQpZBtyNc

Says “To be provided @ the Closing, if any”

Quarter just posted for 5/31/2024

https://www.otcmarkets.com/otcapi/company/financial-report/408374/content

And here’s the MD&A posted

https://www.otcmarkets.com/otcapi/company/financial-report/408376/content

Algernon Announces Increase to Private Placement

Received a email just now but not posted yet OTC but here’s a quote and my math comes to 3,400,000 shares with Warrants the same plus Brokers fee paid in shares

announces an increase to its non-brokered private placement, previously announced on July 11, 2024, from gross proceeds of $250,000 to $408,000 (the “Offering”) of units (the “Units”) at an issue price of $0.12 per Unit. Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to acquire one Common Share (a “Warrant Share”) at an exercise price of $0.24 per Warrant Share for a period of 2 years from the date of issuance (the “Expiry Date”), subject to acceleration of the Expiry Date as described below. The Offering is expected to close on August 1, 2024

That’s $0.12 is $AGN price or $0.087 $AGNPF for the Unit and Warrants are just doubled the price

P.S. ••• It just posted OTC

https://www.otcmarkets.com/stock/AGNPF/news/story?e&id=2933271

Could This Stock Be the Next Bellus Cough Treatment?

https://www.streetwisereports.com/article/2024/07/17/could-this-stock-be-the-next-bellus-cough-treatment.html?utm_source=AGN-CNX

With all of the reverse splits .. my initial 50,000 shares is now 2,000. Lol go figure todays volume.

Looks like everyone split … 1,000 shares traded on some pretty good news

Study Showing 93% Cough Suppression with Ifenprodil

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Reports-Results-of-Study-Showing-93-Cough-Suppression-with-Ifenprodil?id=446850

2,083,333 Units Per this Filing

https://webfiles.thecse.com/Algernon_CSE_Form_9_-_Juy_2024.pdf?xwI_B_aF3yzpRKAETnDXGgVEQpZBtyNc

Algernon Pharmaceuticals Announces Private Placement

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Private-Placement?id=446532

gross proceeds of $250,000 (the “Offering”) of units (the “Units”) at an issue price of $0.12 per Unit

And thats CAD not USD so that $0.088 $AGNPF
on roughly 2,083,784 more diluted shares

Outstanding: 21,940,779 for July 10, 2024

Monthly 5th Report

https://webfiles.thecse.com/6._Algernon_-_CSE_Form_7_-_June_2024.pdf?75v3v4P.m.qiZNOTcs14RpT7cYj_RqOU

Thank you,
It’s a p1 ..
It’s over..
Let’s go P2..

Dr Heijden did the presentation about CHDR at the Psychedelic conference,,,

https://www.icpr-conference.com/speakers/katelijne-van-der-heijden

Seems the Defense Authorization bill has support for research using these drugs for PTSD and "wounds of war". TBA?
The Netherlands is also doing research along with Arizona, Texas and Oregon and more.
Come on Chris, present our research, tell us how it went and try to get us involved with this new funding...JMHFO...GLTA...

https://www.youtube.com/shorts/8b50ODFdMEY

Anyone have presentation?

Outstanding: 21,940,779 for June 6, 2024

Monthly 5th Report

https://webfiles.thecse.com/5._Algernon_-_CSE_Form_7_-_May_2024.pdf?P_P1hgWsY8Cb0IuHXny8OiFIIn_NDM5g

AGN presentation to CHDR later this week. Sure hope we can finally see some real interesting news...GLTA...

Doubled the $$$’s in 3 mo’s…gonna rocket!!!$$$

Insiders look to be Adding Shares

https://ceo.ca/agn

Like the action

NOTICE OF PROPOSED RESTRICTED SHARE UNIT (“RSU”) GRANT OR AMENDMENT

https://webfiles.thecse.com/CSE-Form-11-Notice-of-Proposed-RSUs_-_May_2024.pdf?vrVtJyueWiaIaZ1W3q33kPWkymhn1Uba

Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Engages-ICP-Securities-Inc-for-Automated-Market-Making-Services?id=441221

Nice volume today

Outstanding: 21,840,722 for May 3, 2024

Monthly 5th Report

https://webfiles.thecse.com/4._Algernon_-_CSE_Form_7_-_April_2024.pdf?qaY9FopqdvCRcwssqB4AcLx7jW9LSh5C

200,000 commons to Maxim Group LLC for finding and Closing the Deal with Seyltx, Inc.

MDA filed today

https://webfiles.thecse.com/Algernon_-_MDA_-_February_29_2024.pdf?.kcXKKzsfZ43UIXaVuoDeMZgpfvFHMMH

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-and-the-Centre-for-Human-Drug-Research-to-Present-DMT-Phase-1-Stroke-Clinical-Data-at-the-Interdis?id=437889

Q&A and Webinar

Here is the link to the recording from last week’s webinar:

Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-CEO-Christopher-J-Moreau-to-Be-Featured-on-Radius-Researchs-Pitch-Deep-Dive-and-QA-Webinar-on-A?id=436475

Outstanding: 21,640,762 for April 4, 2024

Monthly 5th Report

https://webfiles.thecse.com/Algernon_-_CSE_Form_7_-_March_2024.pdf?Is_B3LCsJTGbo_e6ku57Z2tafpM1IKDQ

Is algernon neuro a traded stock by itself.

So no treatment for schemic stroke..
They do minimal things and then wait to see how bad the CNS was damaged..
Than try to rebuild what is lost..


When our drug roves itself..
It will need to be purchased everywhere
Stroke victims have access to treatment.. as the sooner you treat the better..

Our drug will not wait for patients .. caregivers will have to stick it..
Every ambulance, every hospital.. perhaps even every urgent care with me..

Depending on test for type of stroke and Pharma delivery system.. this could be like
Overdose or allergy med.. where they encourage everyone to have..
Depends on stroke test and safety of drug..
Micro dose DMT should be very safe..

That is worldwide in an aging population with increasing cardio system weakness..


$2million in bank.. if they can find clinical partner to share development cost with..
We are very blessed to be here

Neuroplasticity, dendritic spines, 1hr 40mins. He sites many papers, mostly in mouse/rat trials, in this presentation where neuroplasticity is observed, but it seems that the AGN 'microdosing for Stroke' concept is unique.



Yes, the when and where type of data for the clinical trials could be announced soon. Maybe Oregon where it's legal for research?
I've held this long already and will hold through the finish...
...GLTA...

The valuations are going to skyrocket on a positive phase 2a

I had found this presentation a long time ago. Finally found it again and it is a great video including neuroplasticity.

Sure great to see this all finally progressing.

“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,” said Christopher J. Moreau CEO of Algernon. “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”

Phase 2a Stroke Study Design

Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo. The primary outcome measure of the study will be safety, and information will be gained on measures of efficacy including preservation of brain tissue, motor recovery, depression and numerous biomarkers linked to the pathophysiology of stroke.

The veteran community has discussed TBI and PTSD issues and treatments involving Psycs. This group may also be a area of recruitment for future stroke/TBI research. There are already a few PTSD studies...

...GLTA...

Algernon going to move forward with 40 patient phase 2 for isechemic stroke.

Is there a Stroke Victim advocacy group which could help cover costs?

Can’t wait for results! 6 days of treatment..
40 patients.. normally a clinical trial takes forever..

How common is an ischemic stroke?

Strokes are very common. Worldwide, strokes rank second among the top causes of death. In the United States, they rank fifth. Strokes are also one of the leading causes of disability worldwide. Ischemic strokes make up about 85% of all strokes.

No shortage of need..

Stroke statistics
In 2021, 1 in 6 deaths from cardiovascular disease was due to stroke.1
Every 40 seconds, someone in the United States has a stroke.2 Every 3 minutes and 14 seconds, someone dies of stroke.1
Every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes.2
About 185,000 strokes—nearly 1 in 4—are in people who have had a previous stroke.2
About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.2
Stroke-related costs in the United States came to nearly $56.5 billion between 2018 and 2019.2 This total includes the cost of health care services, medicines to treat stroke, and missed days of work.
Stroke is a leading cause of serious long-term disability.2 Stroke reduces mobility in more than half of stroke survivors age 65 and older.2

I think the goal will be to administer the first sub psych dose of DMT immediately after diagnosis..

A positive phase 2a.. would be a very large step for algernon

“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,